Diatos S.A. Announces Start of the Preclinical Toxicology Program of DTS-108, a Second Generation Irinotecan

Paris, France, 17 October 2007 – Diatos SA, an international biopharmaceutical company focusing on the research, development and commercialization of targeted anti-cancer drugs, announced today the start of its regulatory toxicology program of DTS-108, with a Phase I trial planned in the first half of 2008. DTS-108 is a Vectocell® based prodrug of SN38, the active metabolite of irinotecan that is currently used for the treatment of colon and lung cancer.